Closing out their discussion on the management of plaque psoriasis, panelists share their excitement for future directions in care.
Experts reflect on the treatment of patients with plaque psoriasis during the COVID-19 pandemic.
A brief discussion on the unmet needs and ongoing challenges in the treatment of plaque psoriasis.
Shared insight on which factors are most important in determining second-line therapy for plaque psoriasis.
Moving on to the second patient case, panelists discuss switching therapy at treatment failure for plaque psoriasis.
Panelists share which factors they use to determine optimal therapy in the moderate to severe plaque psoriasis setting.
A panel of experts reflect on the toxicity profiles of biologic agents used to treat patients with plaque psoriasis.
A focused discussion on the benefit of bimekizumab, an IL-17A/IL-17F inhibitor, in the setting of moderate to severe plaque psoriasis.
A brief review of biologic agents being used or evaluated in the setting of plaque psoriasis.
Taking a broader look at moderate to severe plaque psoriasis, experts consider what the standard of care would be in different settings.